New sites available now on Bearcats Landing
Visit the new sites launched on Bearcats Landing at my.uc.edu (UC login required)
UC Faculty and staff now have even more content to visit in Bearcats Landing, UC's intranet.
Visit the New Sites Launched (Spring Semester 2022) Bearcats Landing news article (UC Login required) to learn more about the following areas' new sites:
What is Bearcats Landing?
Bearcats Landing is a desktop and mobile-friendly platform that develops and strengthens university-wide partnerships to support our future-facing evolution. It provides UC faculty and staff with the role-based tools and resources they need to increase communication and engagement.
Bearcats Landing is UC’s employee home base to read news and announcements, discover events and workshops, and find information essential to keeping the university running smoothly. It works to strengthen our professional community and capitalizes on our workplace diversity to empower individuals to be leaders in workplace. Even as our community grows more remote, we are still connected through the information-sharing and collaboration that takes place on Bearcats Landing.
Related Stories
UC faculty and staff among Rising Star leadership honorees
January 5, 2026
Two UC faculty and staff members are among this year's Rising Star leadership program sponsored by YWCA Greater Cincinnati. Kelli Beecher, assistant professor in the UC College of Nursing, and Brittany Bibb, assistant director of programs and operations in the UC Division of Student Affairs, are among the emerging leaders of 2026. They were featured in the publication Movers & Makers.
What's behind the mysterious rise of migraines?
January 5, 2026
Weather patterns such as extreme heat and storm conditions have been linked to migraine attacks, and research shows those environmental conditions are becoming more common. As National Geographic recently reported, one of the leading theories behind this mysterious rise is that climate change may be playing a role.
Top six 2025 nephrology drug approvals
January 5, 2026
“2025 has been a landmark year for kidney disease therapeutics, marked by a comprehensive slate of FDA approvals covering endothelin-receptor blockade, complement inhibition, GLP-1-based metabolic protection, and B-cell-directed therapy,” Prakash Gudsoorkar, MD, associate professor of clinical medicine at the University of Cincinnati College of Medicine and staff nephrologist at UC Health, recently told MedCentral.